摘要
目的分析予以急性脑梗死患者尤瑞克林、依达拉奉联合治疗的临床效果。方法104例急性脑梗死患者,随机分为对照组和观察组,每组52例。对照组采用依达拉奉治疗,观察组采用尤瑞克林+依达拉奉治疗。比较两组患者治疗效果、不良反应发生情况、美国国立卫生研究院卒中量表(NIHSS)评分以及白介素-17(IL-17)、超敏C反应蛋白(hs-CRP)水平。结果治疗后,观察组治疗总有效率92.31%高于对照组的76.92%,差异具有统计学意义(P<0.05)。观察组不良反应发生率5.77%与对照组的3.85%比较,差异无统计学意义(P>0.05)。治疗2周后,观察组NIHSS评分(4.80±1.05)分、IL-17(33.80±9.50)ng/L、hs-CRP(4.60±1.20)mg/L均低于对照组的(10.05±1.50)分、(59.50±11.50)ng/L、(9.85±1.50)mg/L,差异均具有统计学意义(P<0.05)。结论尤瑞克林+依达拉奉治疗在协同作用基础上提升了急性脑梗死的治疗效果,降低过度炎症应答,安全性理想。
Objective To analyze the clinical effect of urinary kallidinogenase combined with edaravone in the treatment of acute cerebral infarction.Methods A total of 104 patients with acute cerebral infarction were randomly divided into a control group and an observation group,with 52 cases in each group.The control group was treated with edaravone,and the observation group was treated with urinary kallidinogenase and edaravone.The therapeutic effect,occurrence of adverse reactions,National Institutes of Health stroke scale(NIHSS)score,interleukin-17(IL-17)and high-sensitivity C-reactive protein(hs-CRP)levels were compared between the two groups.Results After treatment,the total effective rate of the observation group was 92.31%,which was higher than 76.92%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 5.77%,which had no statistically significant difference compared with 3.85%in the control group(P>0.05).After 2 weeks of treatment,the NIHSS score(4.80±1.05)points,IL-17(33.80±9.50)ng/L,and hs-CRP(4.60±1.20)mg/L of the observation group were lower than(10.05±1.50)points,(59.50±11.50)ng/L and(9.85±1.50)mg/L of the control group,and the difference was statistically significant(P<0.05).Conclusion Combination of urinary kallidinogenase and edaravone can improve the therapeutic effect of acute cerebral infarction on the basis of synergistic effect,reduce excessive inflammation response,and has ideal safety.
作者
邓浩
DENG Hao(Department of Internal Medicine-Neurology,Dandong Central Hospital,Dandong 118000,China)
出处
《中国现代药物应用》
2021年第16期90-92,共3页
Chinese Journal of Modern Drug Application
关键词
尤瑞克林
依达拉奉
急性脑梗死
临床疗效
Urinary kallidinogenase
Edaravone
Acute cerebral infarction
Clinical efficacy